Customs & Import Duty Guide: Exporting Medicines to Nigeria
Introduction
Exporting medicines to Nigeria changed significantly in 2026, and any exporter working from older information is operating on an outdated picture. This guide covers what’s actually current — including a major policy shift that directly affects finished pharmaceutical exports from India — alongside the customs classification, duty calculation, and clearance process that still apply to what remains importable.
What WHO-GMP Certification Actually Confirms
Effective April 1, 2026, Nigeria’s Federal Ministry of Finance introduced a revised Import Prohibition List banning the importation of medicaments — pharmaceutical products — from countries outside the Economic Community of West African States (ECOWAS), as part of the 2026 Fiscal Policy Measures. Since India is not an ECOWAS member, this ban applies directly to finished-dosage exports from Indian manufacturers.
The banned category covers medicaments under HS Codes 3003.10.00.00 through 3004.90.90.00, including common products such as paracetamol tablets and syrups, metronidazole, cotrimoxazole, and chloroquine. Other widely used products — multivitamin capsules, aspirin, folic acid, and ointments such as penicillin and gentamicin — are now restricted to local manufacturers, while importation of pharmaceutical waste under HS Code 3006.92.00.00 remains separately and strictly forbidden.
Why this matters right now: Nigeria has historically sourced 60–65% of its medicines from abroad, especially Active Pharmaceutical Ingredients, and the policy shift is designed to cut that import dependence, conserve foreign exchange, and push local manufacturing to the forefront. Industry groups including the Pharmaceutical Society of Nigeria have raised concerns that domestic manufacturing capacity isn’t yet positioned to absorb this shift. Local manufacturers cite steep operating challenges — energy costs alone account for roughly 40% of overall manufacturing cost, with many plants running on diesel or petrol generators due to unreliable grid supply.
What This Means for Indian Exporters
Finished Dosage Forms Are Largely Restricted
Common generic finished products — many of the categories exporters have traditionally shipped to Nigeria — now fall under the ban when sourced from non-ECOWAS countries. This affects standard tablet, syrup, and capsule exports covered by the listed HS codes.
APIs Remain Importable, Under Permit
NAFDAC’s own March 2026 guidelines for the importation of Active Pharmaceutical Ingredients confirm that API imports continue, requiring an import permit application detailing the applicant’s address, the API source location, the specific APIs involved, and the purpose — whether importation, distribution, sale, or manufacturing of a finished pharmaceutical product. This tracks with the underlying reality that Nigerian pharmaceutical manufacturers still heavily depend on imported APIs, since the country lacks a functional petrochemical industry capable of producing them locally.
This is a significant opening for Indian exporters: rather than exporting finished paracetamol or metronicazole tablets, supplying the APIs that Nigerian manufacturers need to produce them domestically remains a viable, permitted route.
Specialized and Non-Locally-Produced Medicines May Still Have a Path
The ban’s stated intent is to protect domestic manufacturing of commonly produced medicines. Products Nigeria doesn’t manufacture domestically — including many oncology, specialized antiretroviral, and other niche formulations — warrant individual verification against the current prohibition list and NAFDAC guidance, since blanket assumptions in either direction are risky.
ECOWAS-Sourced Goods Are Exempt
The restriction applies specifically to goods originating from non-ECOWAS member states, effectively encouraging regional trade within West Africa. This doesn’t open a direct path for Indian exporters, but it’s relevant context for understanding the policy’s regional trade logic.
Standard Customs Process (For What Remains Importable)
HS Code Classification
The ban’s stated intent is to protect domestic manufacturing of commonly produced medicines. Products Nigeria doesn’t manufacture domestically — including many oncology, specialized antiretroviral, and other niche formulations — warrant individual verification against the current prohibition list and NAFDAC guidance, since blanket assumptions in either direction are risky.
Duty Calculation
Import duty in Nigeria is calculated using the CIF method — Cost, Insurance, and Freight — with the applicable duty rate from the HS code multiplied by the CIF value. Additional charges include a 7% surcharge on duty, 4% FCS on FOB value, 0.5% ETLS on FOB value, and 7.5% VAT on the cumulative total.
Required Documentation
All imports require Form M, a Pre-Arrival Assessment Report (PAAR), commercial invoice, bill of lading or airway bill, packing list, a Combined Certificate of Value and Origin (CCVO), and proof of duty payment through the NICIS II system. Regulated goods additionally require NAFDAC permits and, where applicable, a SONCAP certificate — all lodged electronically through NICIS II.
Clearance Steps
Customs officers verify goods against declared documentation, examine cargo physically or via scanning, and confirm HS code classification and assessed value. Duty is then assessed based on CIF value and paid in naira through an approved bank before cargo release. Regulated goods require sign-off from the relevant agency — NAFDAC clears food and pharmaceuticals specifically — after which the NCS issues a release order for final delivery.
Practical Steps for Exporters Right Now
âś” Verify your specific product’s HS code against the current prohibition list before committing to any shipment — don’t rely on pre-2026 assumptions about what’s importable
âś” Consider repositioning toward API supply for Nigerian manufacturers who still need imported raw materials to produce banned finished-product categories domestically
âś” Use the Advance Ruling mechanism for any product where classification is unclear, rather than shipping and risking rejection at port
âś” Check whether your specific product is domestically manufactured in Nigeria — specialized products without local production capacity may sit outside the ban’s practical intent, but this needs individual verification, not assumption
âś” Watch for further policy updates, since this is a recently implemented and actively debated policy shift with ongoing industry pushback
Conclusion
Exporting medicines to Nigeria in 2026 looks meaningfully different than it did even a year ago. The finished-dosage import ban from non-ECOWAS countries is a real constraint on the traditional generics export model, but it also opens a clearer opportunity around API supply and specialized products outside Nigeria’s current manufacturing capacity. Exporters who verify their specific product’s status rather than working off outdated assumptions — and who adapt their product mix accordingly — are better positioned than those still planning around the pre-2026 landscape.
Salvavidas Pharma continues to track Nigeria’s evolving import policy closely, supplying both APIs and specialized finished products to Nigerian partners in line with current regulatory requirements.